Ranbaxy Laboratories Ltd has received tentative approval from the US Food and Drug Administration to manufacture and market Tolterodine Tartrate Tablets, 1 mg and 2 mg. Total annual market sales for Tolterodine Tartrate Tablets were $ 98 million (IMS - MAT: June 2005).

Tolterodine Tartrate Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

"We are pleased to receive tentative approval for Tolterodine Tartrate Tablets, which represents a future addition to our generic portfolio of products. The product will be made available at the time of final approval by the US FDA," according to Jim Meehan, Vice President, Sales and Marketing for RPI, USA.